title: Effects of alveolar hypoxia on the pulmonary circulation and lung mechanics after cromolyn sodium and U-60,257 in lambs.
abstract: Because alveolar hypoxia (HYP) triggers pulmonary mast cell degranulation with elaboration of vasoactive mediators such as leukotrienes, we investigated the effects of aerosolized cromolyn sodium (CS), a mast cell stabilizing agent, and U-60,257(U) (a leukotriene blocker) on the circulation, lung mechanics and thromboxane (TXB2) levels in 11 lambs during acute exposure to HYP. Studies were performed in awake, chronically instrumented animals, once after placebo (saline) and again after CS (100 mg; n = 5) or U (90 mg; n = 6). Pulmonary arterial pressure increased 42% during HYP after saline, and 32% and 19% after CS and U, respectively. Pulmonary vascular resistance did not change during HYP after CS or U. Systemic arterial pressure was unchanged after saline and CS but decreased after U; systemic vascular resistance dropped after both CS and U. No changes were seen in tidal volume, lung compliance or airway resistance during HYP after saline or either drug, but minute ventilation increased during HYP in all studies. TXB2 increased during HYP after saline in both studies and was not altered by CS. In contrast, after U, TXB2 decreased. Thus, U more effectively blunted the pulmonary vascular response to HYP than CS and resulted in mild systemic hypotension. The drop in TXB2 after U suggests leukotriene-induced thromboxane synthesis contributes to regulation of pulmonary, and possibly, systemic vasoactivity.
authors.affiliation: Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock 72205.
authors.forename: B J
authors.initials: BJ
authors.lastname: Taylor
authors.forename: T L
authors.initials: TL
authors.lastname: Sziszak
authors.forename: T J
authors.initials: TJ
authors.lastname: Sziszak
authors.forename: A Q
authors.initials: AQ
authors.lastname: Dang
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004205:Cromolyn Sodium / Q000494:pharmacology*; D011464:Epoprostenol / Q000031:analogs & derivatives* / Q000494:pharmacology; D000860:Hypoxia / Q000188:drug therapy*; D008168:Lung / Q000187:drug effects* / Q000502:physiology; D011652:Pulmonary Circulation / Q000187:drug effects*; D012756:Sheep; D013929:Thromboxane B2 / Q000097:blood; D014661:Vasoconstriction / Q000187:drug effects* / Q000502:physiology
chemical_list: D013929:Thromboxane B2; D011464:Epoprostenol; D004205:Cromolyn Sodium; C035296:piriprost